The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A. Portell, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. HawkesSally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, Judith Trotman
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma'. Together they form a unique fingerprint.